Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy BHN Ltd (IINN) delivers innovative respiratory care solutions through its non-invasive INSPIRA ART system and HYLA blood monitoring technology. This page provides investors and healthcare professionals with essential updates on regulatory milestones, product developments, and clinical partnerships shaping the future of critical care.
Access real-time information on FDA clearances, technology evaluations, and strategic collaborations. Our curated news ensures you stay informed about advancements in extracorporeal oxygenation and AI-driven blood analytics without speculative commentary.
Discover updates across key categories including regulatory submissions, clinical trial results, product launches, and global distribution agreements. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to Inspira Technologies' progress in redefining respiratory support systems. Check back regularly for authoritative reporting on innovations addressing acute respiratory failure and ICU resource challenges.
Inspira Technologies OXY announced that its INSPIRA™ ART100 Cardiopulmonary Bypass System has received 510(k) class II clearance from the FDA.
The FDA clearance is a significant milestone for the company, suggesting technological and innovative advancements.
CEO Dagi Ben Noon and Chairman Professor Benad Goldwasser expressed their appreciation for investors and partners and highlighted the strategic importance of this clearance.
Inspira™ Technologies OXY B.H.N. (Nasdaq: IINN, IINNW) has announced the start of production of the INSPIRA ART100 medical device. The device is being contract manufactured by a leading technology company and the first batch will be used in initial sites pending FDA approval.
